{"url_path":"/sec/gctk/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1506983/0001493152-26-023205-index.html","accession_number":"0001493152-26-023205","cik":"0001506983","ticker":"GCTK","issuer_name":"Glucotrack, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506983/0001493152-26-023205-index.html","primary_entity_key":"0001506983","primary_entity_name":"Glucotrack, Inc."},"word_count":1145,"has_tables":true,"body_markdown":"**Item\n1A. Risk Factors.**\n\n \n\nYou\nshould carefully consider the factors discussed in Part I, Item 1A., “Risk Factors” in our Annual Report, which could\nmaterially affect our business, financial position, or future results of operations. Except as disclosed below, there have been no\nmaterial changes from the risk factors previously disclosed under the heading “Risk Factors” in our Annual Report. The\nrisks described in our Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or\nthat we currently deem to be immaterial may also materially adversely affect our business, financial position, or future results of\noperations. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the\nSEC.\n\n \n\n**If\nwe are unable to continue to satisfy the applicable continued listing requirements of Nasdaq, our Common Stock could be delisted, and\nwe and our stockholders could face significant material adverse consequences. In addition, Nasdaq has recently proposed a new $5 million\nmarket value of listed securities requirement that we may not satisfy and therefore could cause our Common Stock to be delisted by Nasdaq\non an imminent basis, if approved by the SEC.**\n\n \n\nIn\norder to remain listed on Nasdaq, we must satisfy minimum financial and other continued listing requirements and standards, including\nthose regarding director independence and independent committee requirements, minimum stockholders’ equity, minimum share price,\nand certain corporate governance requirements (the “Nasdaq Listing Rules”).\n\n \n\nOn\nMay 11, 2026, we received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department\nof Nasdaq notifying us that Nasdaq staff (the “Nasdaq Staff”) has determined to delist our Common Stock from The Nasdaq Capital\nMarket.\n\n \n\nThe\nStaff Determination stated that the bid price of the Common Stock had closed at less than $1.00 per share over the previous 30 consecutive\nbusiness days, from March 27, 2026 through May 8, 2026, and that, as a result, we are not in compliance with Nasdaq Listing Rule 5550(a)(2),\nwhich requires listed securities to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”).\n\n \n\nThe\nStaff Determination further stated that, although companies are typically afforded a 180-calendar day period to regain compliance with\nthe Bid Price Rule, the Company is not eligible for any such compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv). Nasdaq\nStaff cited the fact that we have effected a reverse stock split over the prior one-year period and have effected one or more reverse\nstock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. Accordingly, unless we request\nan appeal by May 18, 2026, our Common Stock will be scheduled for delisting and suspended at the opening of business on May 20, 2026.\n\n \n\nWe\nintend to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal Nasdaq Staff’s\ndetermination. A timely hearing request will stay any further delisting actions through the hearing process. At the hearing, we\nexpect to present our plan to regain compliance with the Bid Price Rule. We intend to continue to monitor the closing bid price of\nour Common Stock and will consider available options to regain compliance with the Bid Price Rule, including potentially\nimplementing a reverse stock split (if approved by our stockholders). There can be no assurance that we will be successful in our\nappeal, that the Panel will grant our request for continued listing, or that we will be able to regain compliance with the Bid Price\nRule or maintain compliance with other applicable Nasdaq listing requirements.\n\n \n\nIn\naddition to the foregoing requirements, Nasdaq has recently proposed a new listing requirement that would require each Nasdaq listed\nissuer to maintain a minimum market value of listed securities of at least $5 million. Under this proposal, if the value of an issuer’s\nlisted securities, as measured by each applicable trading day’s closing price, continues to be less than $5 million for a period\nof 30 consecutive trading days, the issuer’s securities would immediately be delisted, with no compliance or cure period. The proposed\nrule would also preclude an issuer’s ability to seek stay of delisting during any appeals process, and would preclude Nasdaq hearings\npanels from reversing the delisting determination to situations where there was an error and the company never actually failed to satisfy\nthe requirement. The panel would also not be able to consider any facts indicating that issuer subsequently regained compliance with\nthe requirement or grant an issuer any additional time to regain compliance. The proposed rule is subject to review and approval by the\nSEC, and it is unknown whether the SEC will approve the proposal. If approved by the SEC, the rule could become effective on an imminent\nbasis. Our Common Stock currently trades at levels that are below the $5 million aggregate market value threshold proposed by Nasdaq.\nAs such, if this proposal is approved by the SEC, our Common Stock could be imminently delisted by Nasdaq on this basis.\n\n \n\nWe\nmay be required to monitor our market value of listed securities closely and, if necessary, take actions such as issuing additional securities,\nraising additional capital or undertaking other corporate actions to seek to maintain compliance, any of which could dilute our existing\nshareholders, increase our costs, or divert management’s attention. The risk of a rapid loss of Nasdaq listing, or an actual delisting,\ncould adversely affect investor confidence, the liquidity and trading price of our Common Stock, and our ability to access the capital\nmarkets, and could have a material adverse effect on our business, financial condition and results of operations.\n\n \n\nThere\ncan be no assurance that we will be able to regain compliance with the Bid Price Rule or maintain compliance with the other Nasdaq Listing\nRules. If we are not able to comply with applicable Nasdaq Listing Rules, our shares of Common Stock will be subject to delisting.\n\n \n\n23\n\n \n\n \n\nIf\nNasdaq delists our Common Stock from trading on its exchange for failure to meet comply with the Bid Price Rule, or any other Nasdaq\nListing Rules, we and our stockholders could face significant material adverse consequences including, but not limited to:\n\n \n\n \n●\na limited availability\nof market quotations for our securities;\n\n \n \n \n\n \n●\na reduction in liquidity\nand market price of our Common Stock;\n\n \n \n \n\n \n●\na reduction in the number\nof investors willing to hold or acquire our Common Stock, which could negatively impact our ability to raise equity financing;\n\n \n \n \n\n \n●\na determination that our\nCommon Stock is a “penny stock,” which will require brokers trading in our Common Stock to adhere to more stringent rules,\npossibly resulting in a reduced level of trading activity in the secondary trading market for our Common Stock;\n\n \n \n \n\n \n●\na limited amount of analyst\ncoverage; and\n\n \n \n \n\n \n●\na decreased ability to\nissue additional securities or obtain additional financing in the future."}